Cocrystal Synthesis through Crystal Structure Prediction
Molecular Pharmaceutics · 03.07.2023 · 20 (7) · 3380-3392
DOI: 10.1021/acs.molpharmaceut.2c01098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 06.06.2023. Verfasst von Yuriy A Abramov und 12 weiteren Autor:innen. Beteiligte Einrichtung: XtalPi Inc., 245 Main Street, Cambridge, Massachusetts 02142, United States. Hauptthemen laut MEDLINE: Chemistry, Pharmaceutical. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 83 Literaturangaben.
Abstract (Originalsprache)
Crystal structure prediction (CSP) is an invaluable tool in the pharmaceutical industry because it allows to predict all the possible crystalline solid forms of small-molecule active pharmaceutical ingredients. We have used a CSP-based cocrystal prediction method to rank ten potential cocrystal coformers by the energy of the cocrystallization reaction with an antiviral drug candidate, MK-8876, and a triol process intermediate, 2-ethynylglyclerol. For MK-8876, the CSP-based cocrystal prediction was performed retrospectively and successfully predicted the maleic acid cocrystal as the most likely cocrystal to be observed. The triol is known to form two different cocrystals with 1,4-diazabicyclo[2.2.2]octane (DABCO), but a larger solid form landscape was desired. CSP-based cocrystal screening predicted the triol-DABCO cocrystal as rank one, while a triol-l-proline cocrystal was predicted as rank two. Computational finite-temperature corrections enabled determination of relative crystallization propensities of the triol-DABCO cocrystals with different stoichiometries and prediction of the triol-l-proline polymorphs in the free-energy landscape. The triol-l-proline cocrystal was obtained during subsequent targeted cocrystallization experiments and was found to exhibit an improved melting point and deliquescence behavior over the triol-free acid, which could be considered as an alternative solid form in the synthesis of islatravir.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- XtalPi Inc., 245 Main Street, Cambridge, Massachusetts 02142, United States.
- Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
- Computational and Structural Chemistry, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States.
- XtalPi, Inc., Shenzhen Jingtai Technology Co., Ltd., Futian District, Shenzhen 518100, China.
- Analytical Research and Development, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States.
ORCID-Profile: Luca Iuzzolino, C Scott Shultz, Sivakumar Sekharan, Alfred Y Lee
Zitieren
APA
Abramov, Y. A., Iuzzolino, L., Jin, Y., York, G., Chen, C. H., Shultz, C. S., Yang, Z., Chang, C., Shi, B., Zhou, T., Greenwell, C., Sekharan, S., & Lee, A. Y. (2023). Cocrystal Synthesis through Crystal Structure Prediction. Molecular Pharmaceutics, 20(7), 3380-3392. https://doi.org/10.1021/acs.molpharmaceut.2c01098
Vancouver
Abramov YA, Iuzzolino L, Jin Y, York G, Chen CH, Shultz CS, et al. Cocrystal Synthesis through Crystal Structure Prediction. Molecular Pharmaceutics. 2023;20(7):3380-3392. doi:10.1021/acs.molpharmaceut.2c01098
BibTeX
@article{Abramov2023,
author = {Abramov, Yuriy A and Iuzzolino, Luca and Jin, Yingdi and York, Gregory and Chen, Chien-Hung and Shultz, C Scott and Yang, Zhuocen and Chang, Chao and Shi, Baimei and Zhou, Tian and Greenwell, Chandler and Sekharan, Sivakumar and Lee, Alfred Y},
title = {Cocrystal Synthesis through Crystal Structure Prediction},
journal = {Molecular Pharmaceutics},
year = {2023},
volume = {20},
number = {7},
pages = {3380--3392},
doi = {10.1021/acs.molpharmaceut.2c01098}
}
EUVIMED